Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis

Ridder, Dirk De; Aa, Frank Van der; Debruyne, Jan; D'hooghe, Marie B; Dubois, Bénédicte; Guillaume, Daniel; Heerings, Marco; Ilsbroukx, Stephan; Medaer, Robert; Nagels, Guy; Seeldrayers, Pierrette; Landegem, W. Van; Willekens, Barbara; Zicot, Anne-Françoise

doi:10.1016/j.clineuro.2013.06.018

Cited by 46 publications

(40 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several European national panels have published their own MS management consensus [17][18][19][20], although, they are mainly based on studies with low levels of evidence. While all groups advocate urological evaluation of symptomatic patients, the recommended approaches for asymptomatic patients are partially divergent and do not reach consensus [17][18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…The International Scientific Committee of the 5 th International Consultation on Incontinence on 2012 has formulated general recommendations for the diagnosis of neurogenic lower urinary tract dysfunction (NLUTD): a) patients with neurologic disease known to be associated with NLUTD should be evaluated for the presence of lower urinary tract symptoms; b) urodynamic tests should selectively be employed to supplement clinical assessment in determining management in NLUTD; c) sphincter EMG can be valuable in the diagnosis of patients with neurologic bladder dysfunction and can be considered as a diagnostic method in patients with NLUTD and neurologic urinary incontinence [15]. Several European national panels have published their own MS management consensus [17][18][19][20], although, they are mainly based on studies with low levels of evidence. While all groups advocate urological evaluation of symptomatic patients, the recommended approaches for asymptomatic patients are partially divergent and do not reach consensus [17][18][19][20].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis

Haggiag

Bolla

Picconi³

et al. 2017

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

Objective: To assess the association between objective bladder function parameters in relation to urinary symptoms, and to analyze the sensitivity and specificity of subjective urinary symptom-assessment in predicting objective bladder dysfunction in a multiple sclerosis (MS) population. Methods: Consecutive MS patients with Expanded Disability Status Score (EDSS) ≤7.0 were included in this prospective study. In a single visit, patients were evaluated for the presence of urinary symptoms, then assessed for the following urological parameters: maximum urinary flow rate (Qmax), postvoid residual urine volume (PVR), and detrusor sphincter dyssinergia (DSD). Results: One hundred nine subjects were included with a mean disease duration of 12.5 ± 8.7 years, 90.8% had a relapsing-remitting course; the mean EDSS score was 2.6 ± 1.7. Overall, 53.5% complained of at least one urinary symptom, and the most reported one was urgency (40.7%), followed by frequency (15.7%) and incomplete emptying (12.0%). Abnormal values were found for Qmax in 34.9%, for PVR in 40.4% of participants; DSD was diagnosed in 33.9% of the cases. Only Qmax was found negatively associated with the EDSS score (p = 0.007), but no other association was observed. The presence of urinary symptoms was poor predictor of bladder dysfunction, urgency among the others showed relatively higher predicting value. Conclusions: Subjective urinary symptoms assessment failed in predicting bladder function. Our results confirmed the value of objective urological assessment in patients with MS, irrespective of the presence of urinary symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis

Haggiag

Bolla

Picconi³

et al. 2017

Mult Scler Demyelinating Disord

View full text Add to dashboard Cite

show abstract

“…Data of its use in MS patients are sparse, especially in women. However, many European consensuses 12,14,15 still recommend it for voiding symptoms, mainly in men with suspected contribution of benign prostatic obstruction.…”

Section: 27mentioning

confidence: 99%

“…Few European consensuses 4,14,15 have recommended IC initiation whenever PVR exceeds 100-150 cc. However, not all MS patients will benefit from a rigid PVR cutoff for initiation of IC (100-150 cc).…”

Section: Intermittent Catheterizationmentioning

confidence: 99%

See 1 more Smart Citation

Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Aharony

Lam

Corcos

2017

CUAJ

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a unique neurological disease with a broad spectrum of clinical presentations that are time-and disease course-related. Lower urinary tract symptoms (LUTS) are highly prevalent in this patient population, with approximately 90% showing some degree of voiding dysfunction and/or incontinence 6-8 years after the initial MS diagnosis. Major therapeutic goals include quality of life improvement and the avoidance of urological complicationsOwing to the wide divergence of clinical symptoms and disease course, evaluation and treatment differ between patients. Treatment must be customized for each patient based on disease phase, patient independence, manual dexterity, social support, and other medical-or MS-related issues. Ablative or irreversible therapies are indicated only when the disease course is stable. In most cases of "safe" bladder, behavioural treatment is considered first-line defense. Antimuscarinic drugs, alone or in combination with intermittent self-catheterization, are currently the mainstay of conservative treatment, and several other medications may help in specific disease conditions. Second-line treatment includes botulinum toxin A injection, neuromodulation, indwelling catheters, and surgery in well-selected cases.

show abstract

Basic Urodynamics and Fundamental Issues

Drake

Gammie

Thomas

et al. 2021

Abrams’ Urodynamics

View full text Add to dashboard Cite

Consensus guidelines on the neurologist's role in the management of neurogenic lower urinary tract dysfunction in multiple sclerosis

Cited by 46 publications

References 50 publications

Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis

Discrepancies between urinary symptoms assessment and objective bladder dysfunctions in multiple sclerosis

Treatment of lower urinary tract symptoms in multiple sclerosis patients: Review of the literature and current guidelines

Basic Urodynamics and Fundamental Issues

Contact Info

Product

Resources

About